Ana içeriğe atla

Report: Covid-19 patients recovering quickly after getting experimental drug remdesivir

Report: Covid-19 Patients Recovering Quickly After Getting Experimental Drug Remdesivir


Covid-19 patients who are getting an experimental drug called remdesivir have been recovering quickly, with most going home in days, STAT News reported Thursday after it obtained a video of a conversation about the trial.
The patients taking part in a clinical trial of the drug have all had severe respiratory symptoms and fever, but were able to leave the hospital after less than a week of treatment, STAT quoted the doctor leading the trial as saying.
"The best news is that most of our patients have already been discharged, which is great. We've only had two patients perish," Dr. Kathleen Mullane, an infectious disease specialist at the University of Chicago who is leading the clinical trial, said in the video.
Mullane did not immediately respond to a request for comment from CNN.
The University of Chicago said Mullane's comments constituted partial information.
"Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions about the safety or efficacy of a potential treatment that is under investigation," it said in a statement.
"In this case, information from an internal forum for research colleagues concerning work in progress was released without authorization. Drawing any conclusions at this point is premature and scientifically unsound."
There is no approved therapy for the Covid-19, which can cause severe pneumonia and acute respiratory distress syndrome in some patients. But the National Institutes of Health is organizing trials of several drugs and other treatments, among them remdesivir.
The drug, made by Gilead Sciences, was tested against Ebola with little success, but multiple studies in animals showed the drug could both prevent and treat coronaviruses related to Covid-19, including SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome).
Back in February, the World Health Organization said remdesivir showed potential against Covid-19.
STAT said it obtained and viewed a copy of the video discussion Mullane had last week with colleagues about the trial.
"Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesn't have to be 10 days," she was quoted as saying.
However, the trial does not include what's known as a control group, so it will be difficult to say whether the drug is truly helping patients recover better. With a control arm, some patients do not receive the drug being tested so that doctors can determine whether it's the drug that is really affecting their condition.
Trials of the drug are ongoing at dozens of other clinical centers, as well. Gilead is sponsoring tests of the drug in 2,400 patients with severe Covid-19 symptoms in 152 trial sites around the world. It's also testing the drug in 1,600 patients with moderate symptoms at 169 hospitals and clinics around the world.
Gilead said it expected results from the trial by the end of the month.
"We understand the urgent need for a COVID-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir," the company said in a statement to CNN. But it said a few stories about patients are just that -- stories.
"The totality of the data need to be analyzed in order to draw any conclusions from the trial. Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19," Gilead said.

Yorumlar

Yorum Gönder

Bu blogdaki popüler yayınlar

Why COVID-19 makes a compelling case for the wider integration of blockchain

Why COVID-19 Makes A Compelling Case For The Wider İntegration Of Blockchain The COVID-19 crisis has revealed a general lack of connectivity and data exchange built into our global supply chains. Future resiliency will depend on building transparent, inter-operable and connective networks. When it became clear that many of us would soon be working from home, a majority took a cursory glance at their home office set-ups and decided it needed upgrading. What ensued was an unanticipated rush and surge of online orders for office desks, chairs, lamps and computer hardware. But such was the sudden spike that it has unsurprisingly caught suppliers large and small unprepared, off guard and exposed gaping holes in their ability to track purchases from one end of their supply chains to the other. Some customers, who have spent no small amount on revamping their home offices are still waiting to do so, without the consolation of being able to see where their orders are, or when they...
Yorum Gönder
Devamı

Covering the coronavirus pandemic: CNN correspondents reflect on how we got here

Covering the coronavirus pandemic: CNN correspondents reflect on how we got here Atlanta (CNN) As the entire world grapples with the effects of the coronavirus outbreak, it is easy to lose sight of how we got here. There are not many news events in recent memory that have come close to the far-reaching implications in terms of our public health, social interactions, and the global economy; life as we know it has been altered. From the beginning, CNN journalists have covered this unprecedented story from all corners of the globe. Three months since we heard the first whispers of a strange respiratory illness emerging in China, this is the story of a story  from those who have witnessed and reported on it firsthand. Wuhan: Ground Zero On the final day of 2019, the World Health Organization receives word of a pneumonia-like disease in the central Chinese city of Wuhan. According to Wuhan Municipal Health, the cases occur between December 12 and December 29. The...
Yorum Gönder
Devamı

Coronavirus at meatpacking plants worse than first thought, USA TODAY investigation finds

Coronavirus at meatpacking plants worse than first thought, USA TODAY investigation finds Coronavirus closed Smithfield and JBS meatpacking plants. Many more are at risk. Operators may have to choose between worker health or meat in stores. Tyson Foods installed plastic barriers between worker stations at its meat and poultry plants to protect against transmission of the coronavirus. Arash of coronavirus outbreaks at dozens of meatpacking plants across the nation is far more extensive than previously thought, according to an exclusive review of cases by USA TODAY and the Midwest Center for Investigative Reporting.  And it could get worse. More than 150 of America’s largest meat processing plants operate in counties where the rate of coronavirus infection is already among the nation’s highest, based on the media outlets’ analysis of slaughterhouse locations and county-level COVID-19 infection rates. These facilities represent more than 1 in 3 of the nation’s...
Yorum Gönder
Devamı